• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Geron Corporation

    6/30/25 5:04:21 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GERN alert in real time by email
    S-8 1 gern-sx8_june20252018eip20.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 30, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933

    GERON CORPORATION
    (Exact name of registrant as specified in its charter)

    Delaware75-2287752
    (State or other jurisdiction incorporation or organization)
    (I.R.S. Employer Identification No.)
    919 E. Hillsdale Blvd, Suite 250
    Foster City, California
    94404
    (Addresses of Principal Executive Offices)
    (Zip Code)

    Geron Corporation 2018 Equity Incentive Plan
    Geron Corporation 2014 Employee Stock Purchase Plan
    (Full title of the plans)

    Dawn C. Bir
    Interim President and Chief Executive Officer
    Geron Corporation
    919 E. Hillsdale Blvd, Suite 250
    Foster City, California 94404
    (650) 473-7700
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copies to:
    Chadwick L. Mills
    Cooley LLP
    3 Embarcadero Center, 20th Floor
    San Francisco, California 94111
    (415) 693-2000
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒ Accelerated filer☐
    Non-accelerated filer☐ Smaller reporting company☐
       Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
    ________________________



    EXPLANATORY NOTE AND GENERAL INSTRUCTION E INFORMATION
    This Registration Statement on Form S-8 is being filed by Geron Corporation (the “Registrant”) for the purpose of registering an additional (i) 20,000,000 shares of the Registrant's common stock, par value $0.001 per share (the “Common Stock”) issuable under the Registrant's 2018 Equity Incentive Plan, as amended (the "2018 Incentive Plan") and (ii) 6,000,000 shares of the Registrant's Common Stock issuable under the Registrant's 2014 Employee Stock Purchase Plan, as amended (the "2014 ESPP").

    The additional shares of Common Stock registered hereunder for issuance under the Registrant's 2018 Incentive Plan and 2014 ESPP are of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed by the Registrant and is effective. Accordingly, in accordance with General Instruction E of Form S-8, this Registration Statement incorporates by reference the contents of the following Registration Statements on Form S-8 previously filed by the Registrant: (a) with respect to the shares registered under the 2018 Incentive Plan (i) File no. 333-225190, filed with the Securities and Exchange Commission (the "Commission") on May 24, 2018; (ii) File no. 333-239324, filed with the Commission on June 19, 2020; (iii) File no. 333-258864, filed with the Commission on August 16, 2021; (iv) File no. 333-266795, filed with the Commission on August 11, 2022; and (v) File no. 333-273669, filed with the Commission on August 3, 2023; and (b) with respect to the shares registered under the 2014 ESPP (i) File no. 333-196677, filed with the Commission on June 11, 2014; and (ii) File no. 333-266795, filed with the Commission on August 11, 2022, except, in each case, for “Item 8. Exhibits” with respect to which the exhibit index set forth below is incorporated herein by reference.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
    •the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 27, 2025;
    •the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 7, 2025;
    •the Registrant’s Current Reports on Form 8-K, filed with the Commission on March 11, 2025, March 17, 2025 and May 27, 2025;
    •the information specifically incorporated by reference into the Registrant’s 2024 Annual Report on Form 10-K referred to above from the Registrant’s definitive proxy statement relating to the Registrant’s 2025 annual meeting of stockholders, filed with the Commission on April 8, 2025; and
    •the description of the Registrant’s common stock set forth in the Registrant’s registration statement on Form 8-A, filed with the Commission on June 13, 1996, including any amendments or reports filed for purpose of updating such description.
    All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be
    2


    incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

    Item 8. Exhibits
      Incorporation by Reference
    Exhibit NumberDescriptionExhibit NumberFilingFiling DateFile No.
    4.1
    Restated Certificate of Incorporation
    3.38-KMay 18, 2012000-20859
    4.2
    Certificate of Amendment of the Restated Certificate of Incorporation
    3.18-KMay 18, 2012000-20859
    4.3
    Certificate of Amendment of the Restated Certificate of Incorporation
    3.18-KJune 7, 2019000-20859
    4.4
    Certificate of Amendment of the Restated Certificate of Incorporation
    3.18-KMay 13, 2021000-20859
    4.5
    Certificate of Amendment of the Restated Certificate of Incorporation
    3.18-KJune 2, 2023000-20859
    4.6
    Amended and Restated Bylaws
    3.18-KDecember 15, 2023000-20859
    4.7
    Form of Common Stock Certificate
    4.110-KMarch 15, 2013000-20859
    5.1
    Opinion of Cooley LLP*
    ————
    23.1
    Consent of Ernst & Young LLP, independent registered public accounting firm*
    ————
    23.2
    Consent of Cooley LLP (included in Exhibit 5.1)*
    ————
    24.1
    Power of Attorney (included on the signature page to this Registration Statement)*
    ————
    99.1
    Geron Corporation 2018 Equity Incentive Plan, as amended
    10.1
    8-K
    May 27, 2025
    000-20859
    99.2
    Geron Corporation 2014 Employee Stock Purchase Plan, as amended
    10.2
    8-K
    May 27, 2025
    000-20859
    107
    Filing Fee Table*
    ————
    _____________________
    *    Filed herewith.
    3


    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on June 30, 2025.
    GERON CORPORATION
    By:
    /s/Michelle Robertson
     
    Michelle Robertson
     
    Executive Vice President, Finance, Chief Financial Officer and Treasurer

    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Dawn C. Bir, Michelle Robertson and Scott A. Samuels, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
    4


    Signature Title Date
    /s/Dawn C. Bir
     Interim President and Chief Executive Officer and June 30, 2025
    DAWN C. BIR Director (Principal Executive Officer)  
    /s/Michelle Robertson
     Executive Vice President, Finance, Chief June 30, 2025
    MICHELLE ROBERTSON 
    Financial Officer and Treasurer
    (Principal Financial and Accounting Officer)
      
    /s/Gaurav Aggarwal
     Director June 30, 2025
    GAURAV AGGARWAL
        
    /s/V. Bryan Lawlis
     Director June 30, 2025
    V. BRYAN LAWLIS    
    /s/John McDonald
     Director June 30, 2025
    JOHN MCDONALD    
    /s/Susan M. Molineaux
     Director June 30, 2025
    SUSAN M. MOLINEAUX    
    /s/Elizabeth G. O’Farrell
     Director June 30, 2025
    ELIZABETH G. O’FARRELL    
    /s/Robert J. Spiegel
     Director June 30, 2025
    ROBERT J. SPIEGEL    
    5
    Get the next $GERN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GERN

    DatePrice TargetRatingAnalyst
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    2/26/2025Buy → Neutral
    H.C. Wainwright
    11/5/2024$8.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$7.00Outperform
    Leerink Partners
    4/30/2024$4.50Outperform → Neutral
    Robert W. Baird
    4/29/2024$10.00Buy
    TD Cowen
    More analyst ratings

    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      5/13/25 4:20:43 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:08 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:06 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • FDA Approval for RYTELO issued to GERON CORP

      Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

      6/7/24 12:36:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 372,000 shares of common stock, to 16 newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on June 17, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and

      6/18/25 4:10:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

      New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS Updates on ongoing IMpactMF and IMproveMF trials of imetelstat show progress in advancing the science of telomerase inhibition in the treatment of myelofibrosis Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by cha

      5/28/25 8:30:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 137,000 shares of common stock, to six newly hired employees as an inducement material to their acceptance of employment with Geron. The stock options and RSUs were granted on May 16, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term and vest

      5/19/25 4:15:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Leadership Updates

    Live Leadership Updates

    See more
    • Geron Corporation Announces Departure of Chief Executive Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

      3/11/25 4:02:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy

      11/11/24 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa

      9/9/24 4:15:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 5:46:12 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 9:31:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Geron Corporation

      SC 13G - GERON CORP (0000886744) (Subject)

      11/14/24 6:25:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Robert J. was granted 5,540 shares, increasing direct ownership by 3% to 182,844 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      7/1/25 4:53:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aggarwal Gaurav

      4 - GERON CORP (0000886744) (Issuer)

      5/22/25 5:07:35 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim President and CEO Bir Dawn Carter

      4 - GERON CORP (0000886744) (Issuer)

      5/22/25 5:06:38 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Geron downgraded by Scotiabank with a new price target

      Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

      5/8/25 8:26:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

      2/27/25 6:20:37 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Geron from Buy to Neutral

      2/26/25 12:09:25 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    SEC Filings

    See more
    • SEC Form S-8 filed by Geron Corporation

      S-8 - GERON CORP (0000886744) (Filer)

      6/30/25 5:04:21 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GERON CORP (0000886744) (Filer)

      5/27/25 4:26:47 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Geron Corporation

      SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)

      5/15/25 4:57:13 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    Financials

    Live finance-specific insights

    See more
    • Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial

      5/7/25 7:00:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. Participants m

      3/31/25 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated tre

      2/26/25 7:30:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care